CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Epithelial Ovarian Cancer|Primary Peritoneal|Fallopian Tube Cancer|Endometrioid Ovarian Cancer
DRUG: TORL-1-23|DRUG: TORL-1-23|DRUG: TORL-1-23|DRUG: Pegfilgrastim (drug)
To assess the efficacy of TORL-1-23 as a monotherapy in women with advanced PROC expressing CLDN6, Objective Response Rate (ORR) per RECIST v1.1 by Blinded Independent Central Review (BICR), At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
Duration of Response (DOR), To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by Blinded Independent Central Review (BICR) and investigator assessment, At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months|Objective Response Rate (ORR), To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by investigator assessment, At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months|Progression-free Survival (PFS), To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by Blinded Independent Central Review (BICR) and by investigator assessment, At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months|Overall Survival (OS), To assess additional efficacy outcome measures of TORL-1-23, From time of consent until death or completion of study (Study duration is approximately 40 months)|Incidence and severity of AEs and clinical laboratory abnormalities per CTCAE v5.0, To assess the safety and tolerability of TORL-1-23, From informed consent until 30 days after the last dose of study treatment, approximately 24 months (each cycle is 21 days)|CA-125 response per Gynecological Cancer Intergroup (GCIG) criteria, To assess the pharmacodynamic effects of TORL-1-23, At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.